Works in Alimentary Pharmacology & Therapeutics, 2022, Vol 55, Issue 4

Results: 27

Editorial: safety of ustekinumab in pregnancy—are we there yet?

Published in:

2022

By:

Skejø, Cæcilie;
Vestergaard, Thea;
Julsgaard, Mette

Publication type:

Editorial

Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma? Authors' reply.

Published in:

2022

By:

Kim, Mi Na;
Ahn, Sang Hoon

Publication type:

Editorial

Cover Image.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. i, doi. 10.1111/apt.16823

By:

Danese, Silvio;
Levesque, Barrett G.;
Feagan, Brian G.;
Jucov, Alina;
Bhandari, Bal Raj;
Pai, Rish K.;
Taylor Meadows, Kristen;
Kirby, Brian J.;
Bruey, Jean‐Marie;
Olson, Allan;
Osterhout, Robin;
Van Biene, Courtney;
Ford, Julia;
Aranda, Richard;
Raghupathi, Kartik;
Sandborn, William J.

Publication type:

Article

Editorial: global liver fat accumulation and global health—towards a sustainable development goal. Authors' reply.

Published in:

2022

By:

Lazarus, Jeffrey V.;
Mark, Henry E.;
Rinella, Mary E.;
Colombo, Massimo

Publication type:

Editorial

Letter: towards gender‐stratified colorectal cancer screening and surveillance? Authors' reply.

Published in:

2022

By:

Jodal, Henriette C.;
Løberg, Magnus

Publication type:

Letter to the Editor

Editorial: targeting aberrant hepatic inflammation for treatment of non‐alcoholic steatohepatitis—authors' reply.

Published in:

2022

By:

Safadi, Rifaat;
Braun, Marius;
Francis, Adi;
Milgrom, Yael;
Massarwa, Muhammad;
Hakimian, David;
Hazou, Wadi;
Issachar, Assaf;
Harpaz, Zivit;
Farbstein, Motti;
Itzhak, Inbal;
Lev‐Cohain, Naama;
Bareket‐Samish, Avital;
Silverman, Michael H.;
Fishman, Pnina

Publication type:

Editorial

Editorial: time to eat? Skipping breakfast in metabolic‐associated fatty liver disease—Authors' reply.

Published in:

2022

By:

Xie, Jiarong;
Xu, Lei;
Xu, Chengfu

Publication type:

Editorial

Letter: treatment with subcutaneous CT‐P13 in Crohn's disease patients with intravenous infliximab failure.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 508, doi. 10.1111/apt.16770

By:

Caron, Bénédicte;
Fumery, Mathurin;
Netter, Patrick;
Peyrin‐Biroulet, Laurent

Publication type:

Article

Letter: loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease—authors' reply.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 499, doi. 10.1111/apt.16757

By:

Mahmoud, Remi;
Schultheiss, Johannes P. D.;
Fidder, Herma H.;
Oldenburg, Bas

Publication type:

Article

Letter: combination of common and novel rare NUDT15 variants should also be considered—authors' reply.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 502, doi. 10.1111/apt.16756

By:

Chao, Kang;
Zhu, Xia;
Gao, Xiang

Publication type:

Article

Editorial: time to eat? Skipping breakfast in metabolic‐associated fatty liver disease.

Published in:

2022

By:

Wilechansky, Robert M.;
Simon, Tracey G.

Publication type:

Editorial

Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 401, doi. 10.1111/apt.16753

By:

Danese, Silvio;
Levesque, Barrett G.;
Feagan, Brian G.;
Jucov, Alina;
Bhandari, Bal Raj;
Pai, Rish K.;
Taylor Meadows, Kristen;
Kirby, Brian J.;
Bruey, Jean‐Marie;
Olson, Allan;
Osterhout, Robin;
Van Biene, Courtney;
Ford, Julia;
Aranda, Richard;
Raghupathi, Kartik;
Sandborn, William J.

Publication type:

Article

Editorial: global liver fat accumulation and global health–towards a sustainable development goal.

Published in:

2022

By:

Ayonrinde, Oyekoya T.;
Van Rooyen, Derrick M.

Publication type:

Editorial

Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 389, doi. 10.1111/apt.16749

By:

Scott, Jennifer;
Jones, Andrew M.;
Piper Hanley, Karen;
Athwal, Varinder S.

Publication type:

Article

Editorial: targeting aberrant hepatic inflammation for treatment of non‐alcoholic steatohepatitis.

Published in:

2022

By:

Muthiah, Mark D.;
Siddiqui, Mohammad S.

Publication type:

Editorial

Letter: towards gender‐stratified colorectal cancer screening and surveillance?

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 504, doi. 10.1111/apt.16737

By:

Papastergiou, Vasilios;
Viazis, Nikos;
Mantzaris, Gerassimos J.

Publication type:

Article

Epstein–Barr virus status and immunosuppression use in paediatric autoimmune liver disease.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 455, doi. 10.1111/apt.16708

By:

Nayagam, Jeremy S.;
Heneghan, Michael A.;
Samyn, Marianne;
Joshi, Deepak

Publication type:

Article

Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 446, doi. 10.1111/apt.16700

By:

Allocca, Mariangela;
Craviotto, Vincenzo;
Dell'Avalle, Cecilia;
Furfaro, Federica;
Zilli, Alessandra;
D'Amico, Ferdinando;
Bonovas, Stefanos;
Peyrin‐Biroulet, Laurent;
Fiorino, Gionata;
Danese, Silvio

Publication type:

Article

Editorial: concurrent fatty liver and chronic viral hepatitis: a dual calamity leading to increased risk of hepatocellular carcinoma?

Published in:

2022

By:

Wang, Jennifer;
Pillai, Anjana A.

Publication type:

Editorial

Long‐term colorectal cancer incidence and mortality after adenoma removal in women and men.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 412, doi. 10.1111/apt.16686

By:

Jodal, Henriette C.;
Klotz, Dagmar;
Herfindal, Magnhild;
Barua, Ishita;
Tag, Petter;
Helsingen, Lise M.;
Refsum, Erle;
Holme, Øyvind;
Adami, Hans‐Olov;
Bretthauer, Michael;
Kalager, Mette;
Løberg, Magnus

Publication type:

Article

Letter: loss of response to anti‐TNFα agents in patients with inflammatory bowel disease depends on treatment duration.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 497, doi. 10.1111/apt.16713

By:

Ben‐Horin, Shomron;
Ungar, Bella

Publication type:

Article

Systematic review with meta‐analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 380, doi. 10.1111/apt.16714

By:

Parrot, Laurène;
Dong, Catherine;
Carbonnel, Franck;
Meyer, Antoine

Publication type:

Article

Letter: combination of common and novel rare NUDT15 variants should also be considered.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 501, doi. 10.1111/apt.16719

By:

Wu, Ruiqi;
Fan, Xiaoli;
Yang, Li;
Luo, Xuefeng

Publication type:

Article

Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 434, doi. 10.1111/apt.16697

By:

Liu, Chen‐Hua;
Peng, Cheng‐Yuan;
Kao, Wei‐Yu;
Yang, Sheng‐Shun;
Shih, Yu‐Lueng;
Lin, Chin‐Lin;
Tsai, Meng‐Kun;
Lee, Chih‐Yuan;
Chang, Chun‐Chao;
Wu, Jo‐Hsuan;
Liu, Chun‐Jen;
Su, Tung‐Hung;
Tseng, Tai‐Chung;
Chen, Pei‐Jer;
Kao, Jia‐Horng

Publication type:

Article

Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 422, doi. 10.1111/apt.16691

By:

Myojin, Yuta;
Hikita, Hayato;
Tahata, Yuki;
Doi, Akira;
Kato, Seiya;
Sasaki, Yoichi;
Shirai, Kumiko;
Sakane, Sadatsugu;
Yamada, Ryoko;
Kodama, Takahiro;
Hagiwara, Hideki;
Imai, Yasuharu;
Hiramatsu, Naoki;
Tamura, Shinji;
Yamamoto, Keiji;
Ohkawa, Kazuyoshi;
Hijioka, Taizo;
Fukui, Hiroyuki;
Doi, Yoshinori;
Yamada, Yukinori

Publication type:

Article

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment.

Published in:

Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 464, doi. 10.1111/apt.16712

By:

Sandborn, William J.;
Lawendy, Nervin;
Danese, Silvio;
Su, Chinyu;
Loftus, Edward V.;
Hart, Ailsa;
Dotan, Iris;
Damião, Adérson O. M. C.;
Judd, Donna T.;
Guo, Xiang;
Modesto, Irene;
Wang, Wenjin;
Panés, Julian

Publication type:

Article

Issue Information.

Published in:: Alimentary Pharmacology & Therapeutics, 2022, v. 55, n. 4, p. 377, doi. 10.1111/apt.16414
Publication type:: Article